Acetylsalicylic acid/dipyridamole
Combination of
Acetylsalicylic acidAnticoagulant
DipyridamoleAnticoagulant
Clinical data
Trade namesAggrenox, Asasantin
AHFS/Drugs.comUK Drug Information
Routes of
administration		Oral
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)

The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]

The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events and stroke.[3] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[4]

References

  1. ^ FASS (the Swedish official drug catalog) > Asasantin Last update: 2009–08–17
  2. ^ "Dipyridamole" at Dorland's Medical Dictionary
  3. ^ Malinin AI, Eisert RM, Atar D, Barkagan Z, Serebruany VL (2002). "Aggrenox (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events". Heart Drug. 2 (2): 93–104. doi:10.1159/000063427. S2CID 71396361.
  4. ^ Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH (September 2004). "Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial". European Journal of Pharmacology. 499 (3): 315–24. doi:10.1016/j.ejphar.2004.07.114. PMID 15381054.


Categories